ESR1 and breast cancer: Compared to existing structures of SERMs and SERDs in complex with Y537S ERα LBD, the T6I-29-bound structure is most like raloxifene (RAL), which showed significant anti-transcriptional efficacy in breast cancer cells harboring Y537S ESR1 [24].